S&P 500   4,288.56 (-0.39%)
DOW   34,073.73 (-0.23%)
QQQ   330.70 (-0.48%)
AAPL   175.88 (+1.65%)
MSFT   292.93 (+0.08%)
META   177.27 (-1.23%)
GOOGL   120.69 (-0.83%)
AMZN   142.78 (-1.38%)
TSLA   925.22 (+0.60%)
NVDA   184.93 (-2.04%)
NIO   20.42 (-2.34%)
BABA   90.80 (-2.00%)
AMD   98.78 (-1.42%)
MU   61.85 (-3.15%)
T   18.58 (+0.05%)
CGC   4.17 (+10.32%)
F   16.19 (-1.46%)
GE   80.12 (-1.17%)
DIS   123.91 (-0.84%)
AMC   22.21 (-10.48%)
PYPL   100.75 (-1.30%)
PFE   49.61 (-0.50%)
NFLX   243.09 (-1.06%)
S&P 500   4,288.56 (-0.39%)
DOW   34,073.73 (-0.23%)
QQQ   330.70 (-0.48%)
AAPL   175.88 (+1.65%)
MSFT   292.93 (+0.08%)
META   177.27 (-1.23%)
GOOGL   120.69 (-0.83%)
AMZN   142.78 (-1.38%)
TSLA   925.22 (+0.60%)
NVDA   184.93 (-2.04%)
NIO   20.42 (-2.34%)
BABA   90.80 (-2.00%)
AMD   98.78 (-1.42%)
MU   61.85 (-3.15%)
T   18.58 (+0.05%)
CGC   4.17 (+10.32%)
F   16.19 (-1.46%)
GE   80.12 (-1.17%)
DIS   123.91 (-0.84%)
AMC   22.21 (-10.48%)
PYPL   100.75 (-1.30%)
PFE   49.61 (-0.50%)
NFLX   243.09 (-1.06%)
S&P 500   4,288.56 (-0.39%)
DOW   34,073.73 (-0.23%)
QQQ   330.70 (-0.48%)
AAPL   175.88 (+1.65%)
MSFT   292.93 (+0.08%)
META   177.27 (-1.23%)
GOOGL   120.69 (-0.83%)
AMZN   142.78 (-1.38%)
TSLA   925.22 (+0.60%)
NVDA   184.93 (-2.04%)
NIO   20.42 (-2.34%)
BABA   90.80 (-2.00%)
AMD   98.78 (-1.42%)
MU   61.85 (-3.15%)
T   18.58 (+0.05%)
CGC   4.17 (+10.32%)
F   16.19 (-1.46%)
GE   80.12 (-1.17%)
DIS   123.91 (-0.84%)
AMC   22.21 (-10.48%)
PYPL   100.75 (-1.30%)
PFE   49.61 (-0.50%)
NFLX   243.09 (-1.06%)
S&P 500   4,288.56 (-0.39%)
DOW   34,073.73 (-0.23%)
QQQ   330.70 (-0.48%)
AAPL   175.88 (+1.65%)
MSFT   292.93 (+0.08%)
META   177.27 (-1.23%)
GOOGL   120.69 (-0.83%)
AMZN   142.78 (-1.38%)
TSLA   925.22 (+0.60%)
NVDA   184.93 (-2.04%)
NIO   20.42 (-2.34%)
BABA   90.80 (-2.00%)
AMD   98.78 (-1.42%)
MU   61.85 (-3.15%)
T   18.58 (+0.05%)
CGC   4.17 (+10.32%)
F   16.19 (-1.46%)
GE   80.12 (-1.17%)
DIS   123.91 (-0.84%)
AMC   22.21 (-10.48%)
PYPL   100.75 (-1.30%)
PFE   49.61 (-0.50%)
NFLX   243.09 (-1.06%)
NASDAQ:PCSA

Processa Pharmaceuticals - PCSA Stock Forecast, Price & News

$3.13
-0.13 (-3.99%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.06
$3.29
50-Day Range
$2.59
$3.65
52-Week Range
$1.50
$8.99
Volume
2,582 shs
Average Volume
10,891 shs
Market Capitalization
$49.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Processa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
395.2% Upside
$15.50 Price Target
Short Interest
Healthy
0.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Processa Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$3,180 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

401st out of 1,122 stocks

Pharmaceutical Preparations Industry

195th out of 551 stocks

PCSA stock logo

About Processa Pharmaceuticals (NASDAQ:PCSA) Stock

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

Wall Street Analysts Forecast Growth

Several research analysts have commented on PCSA shares. Maxim Group started coverage on shares of Processa Pharmaceuticals in a research note on Tuesday, April 19th. They set a "buy" rating for the company. Benchmark decreased their price objective on Processa Pharmaceuticals from $15.00 to $9.00 in a report on Friday, May 13th.

Processa Pharmaceuticals Trading Down 4.0 %

Shares of PCSA Stock traded down $0.13 during trading hours on Wednesday, reaching $3.13. 2,582 shares of the company's stock were exchanged, compared to its average volume of 10,891. Processa Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $8.99. The stock has a market cap of $49.64 million, a PE ratio of -3.40 and a beta of -0.11. The stock's fifty day moving average price is $3.12 and its two-hundred day moving average price is $3.12.

Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PCSA Stock News Headlines

PCSA Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals Non-GAAP EPS of -$0.20
See More Headlines
Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PCSA Company Calendar

Last Earnings
11/12/2021
Today
8/17/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PCSA
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+395.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-11,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.27 per share

Miscellaneous

Free Float
11,654,000
Market Cap
$49.64 million
Optionable
Not Optionable
Beta
-0.11














PCSA Stock - Frequently Asked Questions

Should I buy or sell Processa Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCSA shares.
View PCSA analyst ratings
or view top-rated stocks.

What is Processa Pharmaceuticals' stock price forecast for 2022?

2 analysts have issued 12 month target prices for Processa Pharmaceuticals' stock. Their PCSA share price forecasts range from $9.00 to $22.00. On average, they anticipate the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 395.2% from the stock's current price.
View analysts price targets for PCSA
or view top-rated stocks among Wall Street analysts.

How have PCSA shares performed in 2022?

Processa Pharmaceuticals' stock was trading at $4.90 at the beginning of the year. Since then, PCSA shares have decreased by 36.1% and is now trading at $3.13.
View the best growth stocks for 2022 here
.

When is Processa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our PCSA earnings forecast
.

How were Processa Pharmaceuticals' earnings last quarter?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. During the same period in the prior year, the company posted ($0.55) EPS.

What is Processa Pharmaceuticals' stock symbol?

Processa Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCSA."

Who are Processa Pharmaceuticals' major shareholders?

Processa Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Coastal Bridge Advisors LLC (0.33%) and Renaissance Technologies LLC (0.07%). Insiders that own company stock include David Young, James E Besser, James H Stanker, Justin W Yorke, Patrick Lin and Robert Michael Floyd.
View institutional ownership trends
.

How do I buy shares of Processa Pharmaceuticals?

Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Processa Pharmaceuticals' stock price today?

One share of PCSA stock can currently be purchased for approximately $3.13.

How much money does Processa Pharmaceuticals make?

Processa Pharmaceuticals (NASDAQ:PCSA) has a market capitalization of $49.64 million. The company earns $-11,430,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How can I contact Processa Pharmaceuticals?

Processa Pharmaceuticals' mailing address is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. The official website for the company is www.processapharmaceuticals.com. The company can be reached via phone at (443) 776-3133, via email at plin@processapharma.com, or via fax at 443-288-4420.

This page (NASDAQ:PCSA) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.